| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Under this new agreement, Pfizer Ignite will provide strategic guidance and resources to Acepodia as the company develops its cell therapies for oncology and autoimmune diseases.
By collaborating with Pfizer Ignite, Acepodia will benefit from Pfizer's resources, deep expertise and R&D capabilities, covering multiple stages such as clinical trial design and regulatory strategies to improve the process of developing innovative drugs.
With the agreement, Acepodia will retain all rights related to the progress of the program and future partnership opportunities.
Posted In: PFE
